These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35041802)

  • 1. Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease.
    Lin T; Al-Makki A; Shepler B
    J Pharm Pharm Sci; 2022; 25():77-83. PubMed ID: 35041802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
    King AJ; Siegel M; He Y; Nie B; Wang J; Koo-McCoy S; Minassian NA; Jafri Q; Pan D; Kohler J; Kumaraswamy P; Kozuka K; Lewis JG; Dragoli D; Rosenbaum DP; O'Neill D; Plain A; Greasley PJ; Jönsson-Rylander AC; Karlsson D; Behrendt M; Strömstedt M; Ryden-Bergsten T; Knöpfel T; Pastor Arroyo EM; Hernando N; Marks J; Donowitz M; Wagner CA; Alexander RT; Caldwell JS
    Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications.
    Yee J; Rosenbaum D; Jacobs JW; Sprague SM
    Am J Nephrol; 2021; 52(7):522-530. PubMed ID: 34515051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
    Block GA; Rosenbaum DP; Yan A; Chertow GM
    J Am Soc Nephrol; 2019 Apr; 30(4):641-652. PubMed ID: 30846557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
    J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on tenapanor to treat hyperphosphatemia.
    Cianciolo G; Barbuto S; Iacovella F; La Manna G; Galassi A; Ciceri P; Cozzolino M
    Drugs Today (Barc); 2022 Jan; 58(1):33-53. PubMed ID: 35107092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
    Block GA; Rosenbaum DP; Yan A; Greasley PJ; Chertow GM; Wolf M
    Nephrol Dial Transplant; 2019 Feb; 34(2):339-346. PubMed ID: 29617976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
    King AJ; Kohler J; Fung C; Jiang Z; Quach A; Kumaraswamy P; Chertow GM; Rosenbaum DP
    Am J Physiol Renal Physiol; 2021 Jan; 320(1):F133-F144. PubMed ID: 33283643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
    Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Åstrand M; Johansson S; Knutsson M; Langkilde AM; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1933-1942. PubMed ID: 28159782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.
    Nakayama M; Kobayashi S; Kusakabe M; Ohara M; Nakanishi K; Akizawa T; Fukagawa M
    Clin Exp Nephrol; 2024 Feb; 28(2):153-164. PubMed ID: 37910313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
    Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
    Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.
    Fouque D; Vervloet M; Ketteler M
    Drugs; 2018 Aug; 78(12):1171-1186. PubMed ID: 30022383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.
    Spencer AG; Labonte ED; Rosenbaum DP; Plato CF; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Bell N; Tabora J; Joly KM; Navre M; Jacobs JW; Charmot D
    Sci Transl Med; 2014 Mar; 6(227):227ra36. PubMed ID: 24622516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperphosphatemia in Chronic Kidney Disease: The Search for New Treatment Paradigms and the Role of Tenapanor.
    Cernaro V; Longhitano E; Casuscelli C; Peritore L; Santoro D
    Int J Nephrol Renovasc Dis; 2024; 17():151-161. PubMed ID: 38831770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients with Kidney Failure.
    Hill Gallant KM; Sprague SM; Rosenbaum DP; Spiegel DM; Kozuka K; Edelstein S; Chertow GM
    J Ren Nutr; 2024 Jul; ():. PubMed ID: 38992521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
    Labonté ED; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Dy E; Black D; Zhong Z; Langsetmo I; Spencer AG; Bell N; Deshpande D; Navre M; Lewis JG; Jacobs JW; Charmot D
    J Am Soc Nephrol; 2015 May; 26(5):1138-49. PubMed ID: 25404658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenapanor: First Approval.
    Markham A
    Drugs; 2019 Nov; 79(17):1897-1903. PubMed ID: 31677150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
    Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Stefansson BV; Rydén-Bergsten T; Greasley PJ; Johansson SA; Knutsson M; Carlsson BC
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1597-1605. PubMed ID: 27340281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations.
    Cozzolino M; Ketteler M; Wagner CA
    Expert Opin Ther Targets; 2020 May; 24(5):477-488. PubMed ID: 32191548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.